The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 6.47 — safe zoneOK
- Earnings-manipulation signal · Beneish M -4.96 — no flag raisedOK
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as CRISPR Therapeutics AG reports it. History and quarterly detail are in the app.
- Grant$3.5M
Leadership changes
From CRISPR Therapeutics AG's own filings, the day they're filed.
- Julianne Bruno · Chief Operating Officer · departureeff. 2025-04-11
- Phuong Khanh Morrow · Chief Medical Officer · departureeff. 2024-01-26
- Rodger Novak · President · departureeff. 2023-09-15
Latest filings
- 8-K · Company announcement2026-06-04
- 10-Q · Quarterly report2026-05-04
- 8-K · Company announcement2026-05-04
- DEF 14A · Annual proxy (pay & governance)2026-04-21
- 8-K · Company announcement2026-03-16
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about CRISPR Therapeutics AG, every answer cited🔒
- The Intelligence Brief — added when CRISPR Therapeutics AG's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.